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Reactions of 3-nitro-2-triﬂuoro(trichloro)methyl-2H-chromenes, including 2-unsubstituted derivatives,
with N-alkyl-a-amino acids (sarcosine, proline) and paraformaldehyde proceed diastereoselectively to
give 1-benzopyrano[3,4-c]pyrrolidines in good yields as a result of a 1,3-dipolar cycloaddition of the
intermediate nonstabilized azomethine ylide at the D3-bond of the chromene system.














Fig. 1. Benzopyranopyrrolidine drugs candidates.1. Introduction
1,3-Dipolar cycloaddition is one of the most important methods
for the synthesis of ﬁve-membered heterocycles. The high regio-
and stereoselectivity typical of these reactions make them an in-
dispensable tool for synthesizing natural molecules with a few
chiral centers.1 In particular, azomethine ylides derived from
readily available N-alkyl-a-amino acids and carbonyl compounds
enable one-step syntheses of substituted pyrrolidines that are of
considerable interest as compounds with a broad spectrum of
bioactivity.2 On the other hand, chromane derivatives are wide-
spread in the plant world and also possess valuable biological and
pharmacological properties.3 In view of this, combining benzo-
pyran and pyrrolidine moieties in a single molecule seems a syn-
thetic task of current interest.4 cis-Benzopyranopyrrolidine I is an
antagonist of 5-HT2C receptors with respect to 5-HT2A,4c whereas
its more complex derivative II (Fiduxosin) is an a1 adrenoreceptor
antagonist and shows an a1a/a1b selectivity for adrenoreceptors; it
was suggested as a promising pharmaceutical agent for the treat-
ment of benign prostatic hyperplasia5 (Fig. 1).-mail addresses: vyacheslav.
skikh).
All rights reserved.The key stage in the synthesis of benzopyranopyrrolidines is the
cycloaddition of nonstabilized azomethine ylides to coumarins4,6
and 2H-chromenes, however, information about such reactions in
the 2H-chromenes series is quite limited. It is only known that 2-
aryl-3-nitro-2H-chromenes react with azomethine ylides at reﬂux
in toluene for several hours to give the corresponding 4-aryl-3a-
nitrobenzopyrano[3,4-c]pyrrolidines.7 Taking into account the lit-
erature data,8 we envisaged that introduction of such powerful
electron-withdrawing substituents as CF3 and CCl3 groups into the
2-position of 3-nitro-2H-chromenes would increase their reactivity
toward 1,3-dipolar cycloadditionwith various 1,3-dipoles and open
up a broad synthetic scope of these important oxygen-containing
heterocycles. Of particular interest is the fact that introduction of
a triﬂuoromethyl group into bioactive molecules can have profound





a: X = F, R = H (97%) 
b: X = F, R = Br (93%)
c: X = F, R = MeO (77%)




















e: X = Cl, R = H (89%)
f : X = Cl, R = Br (80%)
g: X = Cl, R = MeO (85%)














V.Yu. Korotaev et al. / Tetrahedron 69 (2013) 8602e8608 8603derived ﬂuorinated compounds.9 As a consequence, exploitation of
an efﬁcient method for the synthesis of these compounds is highly
desirable.
2. Results and discussion
3-Nitro-2-trihalomethyl-2H-chromenes 1 (X¼F, Cl), prepared by
tandem condensation of the appropriate salicylaldehydes with
3,3,3-triﬂuoro(trichloro)-1-nitropropenes,10 have not received
much attention despite their potential interest as CF3- and CCl3-
building blocks in organic synthesis for the construction of
trihalomethyl-containing heterocycles. The majority of the re-
actions with these compounds are nucleophilic additions at the 4-
position leading to various types of 4-substituted chromanes.11
Most pertinent to the present research is the hetero-DielseAlder
reaction of 3-nitro-2-trihalomethyl-2H-chromenes 1 with
electron-rich dienophiles, such as ethyl vinyl ether and 2,3-
dihydrofuran, providing a straightforward route to the cyclic
nitronates.12 However, examples of the participation of chromenes
1 in any 1,3-dipolar cycloaddition reactions are lacking, a fact
prompting us to investigate their reaction with the nonstabilized
azomethine ylide derived from N-alkyl-a-amino acids (sarcosine,
proline) and paraformaldehyde, and elucidate the effects of differ-
ent 3-nitro-2H-chromenes on the occurrence and stereoselectivity
of cycloaddition reactions compared to those of 2-aryl-3-nitro-2H-
chromenes.7
Herein, we have found that treatment of 3-nitro-2-
trihalomethyl-2H-chromenes 1aeh with the azomethine ylide
generated in situ from sarcosine and paraformaldehyde in reﬂuxing
toluene for 5e10 min with azeotropic removal of water affords the
desired benzopyrano[3,4-c]pyrrolidines 2aeh in high yields
(77e97%), which were isolated as free bases by crystallization from
dichloromethane/hexane. This indicates that the presence of an
electron-withdrawing trihalomethyl group at the 2-position in-
creases the dipolarophilic reactivity of the 2-CX3-chromenes 1aeh
toward the azomethine ylide, and makes these compounds more
reactive than non-halogenated 3-nitro-2H-chromenes. As is the
case of cycloaddition reactions involving 2-aryl-3-nitro-2H-chro-
menes,7 compounds 2aeh were formed mainly as the cis-isomers
in relation to the nitro and trihalomethyl groups at C-3a and C-4.
The synchronism of the reactions of nonstabilized azomethine
ylides with alkenes results in the cis-fusion of the new pyrrolidine
ring. The appearance of the trans-adducts 20aeh (3e30% according
to the 1H NMR data) was observed only in the crude products. Thus,
the ready accessibility and high reactivity of CX3-chromenes 1aeh
have made them useful substrates for constructing biologically and
medicinally important products (Scheme 1).
The structures of compounds 2aeh were determined by ele-
mental analysis (as their oxalates 3aeh, which were obtained in
almost quantitative yield in acetone) and by comparison of their IR,
1H, and 13C NMR spectra with data for related benzopyr-
anopyrrolidines.6,7 Selected 1H NMR spectroscopic data for com-
pounds 2 and 20 as well as 3 and 30, which conﬁrm the structure, are
collected in Table 1. The 1H NMR spectra of cis-pyrrolidines 2 in
CDCl3 contain the following characteristic signals: a triplet or
a doublet of doublets of the H-10 proton at d 2.2e2.6 ppm
(J¼9.0e11.0 Hz), which is subjected to the shielding effect of the
benzene moiety in the cis-position; a triplet or a doublet of dou-
blets of H-100 at d 3.5e3.8 ppm (J¼7.7e9.0 Hz); doublets of geminal
protons H-30 and H-300 at d 2.7e3.0 and 4.0e4.5 ppm
(J¼11.8e12.2 Hz); a triplet or a doublet of doublets of the H-9b
benzyl proton at d 4.0e4.2 ppm (J¼7.5e10.5 Hz). In the case of
trans-pyrrolidines 20, the strongly shielded proton H-10 at
d 1.8e2.0 ppm and strongly deshielded proton H-4 at d 4.8e5.2 ppm
(this atom exists in the cis-position toward the NO2 group) were
observed as a consequence of the conﬁguration change at C-4.Signiﬁcant variations are observed in the chemical shifts of H-4 on
going from bases cis-pyrrolidines 2 (d 4.3e4.6 ppm in CDCl3) to
their oxalates 3 (d 5.2e5.7 ppm in DMSO-d6). All signals in the 1H
and 13C NMR spectra of compounds 2 and 3 were assigned on the
basis of 2D 1He13C HSQC and HMBC experiments for 2b, 3d, and 3h.
Moreover, the stereochemistry of 2b was unambiguously con-
ﬁrmed by X-ray single crystal analysis (Fig. 2).
In addition to sarcosine, proline was brieﬂy examined in the
reaction. Cycloaddition of the azomethine ylide derived from pro-
line and paraformaldehyde with chromenes 1a,b,f and 3-nitro-2-
phenyl-2H-chromene (1i) occurred in a similar way to give com-
pounds 4aed, which were isolated from a mixture of regio- and
stereoisomers in low yields (11e34%). Obviously, in contrast to the
azomethine ylide from sarcosine, this cycloaddition was less se-
lective. Only the indicated diastereomer could be separated by re-
crystallization of the mixture from diethyl ether and hexane,
however, product 4cwas obtained as a 68:32 mixture of 4cwith its
minor isomer, the structure of which was not determined
(Scheme 2).
The relative stereochemistry in cycloadducts 4b and 4d was
established by 2D 1He1H NOESY experiments. The most important
proof of their stereochemistry was the NOE enhancements in-
dicated with arrows in Fig. 3. All signals in the 1H and 13C NMR
spectra of compounds 4 were assigned on the basis of 2D 1He1H
COSY, 1He13C HSQC, and HMBC experiments of 4b,d. The doublet of
doublets or triplet of the H-11a benzyl proton in compounds 4aed
allows us to rule out the alternative regioisomeric structure, in
which the benzyl proton should interact with only one vicinal
proton. It is necessary to be mentioned that in the case of chro-
menes 1a,e, sarcosine, and benzaldehyde the reaction led to
a mixture of starting materials and unidentiﬁed products.
Next, taking into account the broad utility of benzopyr-
anopyrrolidines in medicinal chemistry,4,5 and the fact that the
literature contains no data on reactions of 2-unsubstituted 2H-
chromenes with nonstabilized azomethine ylides, we studied the
reaction of 3-cyano- and 3-methoxycarbonyl-2H-chromenes 1j,k
with sarcosine and paraformaldehyde. It was found that reﬂuxing
these compounds in benzene gave benzopyrano[3,4-c]pyrrolidines
5a,b, which were isolated as hydrochlorides in high yields
(76e83%). The desired products precipitate upon neutralization of
the reaction mixtures with HCl, prepared in situ from AcCl and i-
PrOH, and a simple ﬁltration provides analytically pure material. In







































Fig. 3. NOE connectivities in compounds 4b and 4d.
Table 1


































Compd 1H NMR (d, ppm)
H(10) H(100) H(30) H(300) H(9b) H(4) H(10) H(100) H(30) H(300) H(9b) H(4)
Cis-isomer 2 Trans-isomer 20
2a 2.45 3.55 2.81 4.02 4.06 4.43 1.89 3.44 2.76 3.99e4.08 4.88
2b 2.48 3.50 2.85 3.97 4.02 4.43 1.92 3.43 2.74 3.94e4.05 4.85
2c 2.43 3.54 2.79 4.02 4.05 4.39 1.89 3.44 2.74 4.01 3.96 4.82
2d 2.62 3.56 3.00 3.91 4.09 4.59 2.04 3.48 2.83 4.02 4.14 4.96
2e 2.25 3.71 2.77 4.51 4.18 4.38 1.83 3.40 3.05 4.10 3.92 5.19
2f 2.25 3.67 2.78 4.48 4.15 4.36 1.83 3.40 3.03 4.09 3.88 5.15
2g 2.23 3.68 2.74 4.50 4.17 4.33 1.84 3.40 3.04 4.09 3.87 5.14
2h 2.34 3.76 2.90 4.48 4.21 4.48 1.90 3.46 3.08 4.11 4.06 5.23
Cis-isomer 3 Trans-isomer 30
3a 2.45 3.73 2.88 4.15 4.02 5.42 a 3.45 2.72 3.94 4.22 a
3b 2.45 3.73 2.88 4.14 4.05 5.46 a 3.44 2.72 3.92 4.24 a
3c 2.44 3.75 2.88 4.14 3.99 5.32 a 3.46 2.67 3.92 4.15 5.28
3d 2.58 3.87 2.99 4.20 4.22 5.69 a 3.47 2.80 3.92 4.28 a
3e 2.46 3.78 3.15 4.40 4.02 5.33 a 3.41 3.00 4.00 4.09 5.22
3f 2.41 3.76 3.08 4.36 4.06 5.39 a 3.40 2.98 3.98 4.11 5.30
3g 2.40 3.77 3.09 4.36 4.00 5.23 a 3.41 2.96 a a 5.12
3h 2.52 3.89 3.17 4.40 4.19 5.63 a a 3.00 4.00 a 5.56




5a: R = CN (76%)
5b: R = CO2Me (83%)
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conditions described above afforded a 2.8:1 mixture of cyclo-



















4a:  R = CF3, R' = H (17%)
4b:  R = CF3, R' = Br (15%)
4c:  R = CCl3, R' = Br (11%)









In conclusion, the use of 3-nitro-2-trihalomethyl-2H-chro-
menes, including 2-unsubstituted derivatives, in 1,3-dipolar cy-
cloadditions of nonstabilized azomethine ylides allows the
V.Yu. Korotaev et al. / Tetrahedron 69 (2013) 8602e8608 8605construction of biologically interesting 1-benzopyrano[3,4-c]pyr-
rolidines in one pot three-component reaction.
4. Experimental
4.1. General
NMR spectra were recorded on Bruker DRX-400 (1Hd400 MHz,
19Fd376 MHz) and AVANCE-500 (1Hd500 MHz, 13Cd126 MHz)
spectrometers in DMSO-d6 and CDCl3 with TMS and C6F6 as internal
standards, respectively. IR spectrawere recorded on a PerkineElmer
Spectrum BX-II instrument as KBr discs. Elemental analysis was
performed on PerkineElmer CHN PE 2400. All solvents used were
dried and distilled per standard procedures. Melting points were
determined without correction. The starting 3-nitrochromenes
1aeh were prepared according to described procedures.10
4.2. General procedure for the preparation of benzopyrano
[3,4-c]pyrrolidines (2aeh)
A mixture of sarcosine (0.23 g, 2.6 mmol), paraformaldehyde
(0.19 g, 6.0 mmol), and the corresponding 3-nitrochromene
(1.0 mmol) was heated under reﬂux in toluene (15 mL) with
a DeaneStark trap for 5e10 min. After that the mixture was con-
centrated under reduced pressure and the solid formed was
washed with dichloromethane/hexane (1:2) to give crude product
as a mixture of two diastereomers 2 and 20. Cis-isomers 2aehwere
prepared after simple recrystallization from dichloromethane/
hexane (1:2) as a colorless powder. Elemental analyses for bases
2aeh were performed for their oxalates 3aeh.
4.2.1. (3aS*,4S*,9bR*)-2-Methyl-3a-nitro-4-(triﬂuoromethyl)-
1,2,3,3a,4,9b-hexahydrochromeno[3,4-c]pyrrole (2a). Yield 97%, mp
76e77 C; IR (KBr): n¼1585, 1548, 1494, 1477, 1457, 1397, 1374,
1338 cm1; 1H NMR (500 MHz, CDCl3): d¼2.38 (s, 3H, Me), 2.45 (t,
1H, H-10, J¼8.7 Hz), 2.81 (d, 1H, H-30, J¼12.2 Hz), 3.55 (t, 1H, H-100,
J¼8.7 Hz), 4.02 (d, 1H, H-300, J¼12.2 Hz), 4.05 (t, 1H, H-9b, J¼8.7 Hz),
4.43 (q, 1H, H-4, J¼5.5 Hz), 7.05e7.12 (m, 2H, H-6, H-8), 7.15 (d, 1H,
H-9, J¼7.0 Hz), 7.24 (t, 1H, H-7, J¼7.7 Hz); 19F NMR (470.5 MHz,
CDCl3): d¼2a (90%) 89.3 (d, CF3, J¼5.5 Hz), 20a (10%) 88.7 (d, CF3,
J¼6.3 Hz); 13C NMR (126 MHz, CDCl3): d¼41.1 (Me), 44.0 (C-9b),
62.4 (q, C-3, 4JC,F¼2.3 Hz), 62.4 (C-1), 76.0 (q, C-4, 2JC,F¼32.4 Hz),
91.2 (C-3a), 117.5 (C-6), 122.0 (C-9a), 122.2 (q, CF3, 1JC,F¼282.9 Hz),
123.7 (C-8), 128.2 (C-9), 128.4 (C-7), 151.7 (C-5a).
4.2.2. (3aS*,4S*,9bR*)-8-Bromo-2-methyl-3a-nitro-4-(triﬂuorometh-
yl)-1,2,3,3a,4,9b-hexahydrochromeno[3,4-c]pyrrole (2b). Yield 93%,
mp 111e112 C; IR (KBr): n¼1552, 1482, 1463, 1409, 1388, 1350,
1333 cm1; 1H NMR (500 MHz, CDCl3): d¼2.38 (s, 3H, Me), 2.48 (t,
1H, H-10, J¼8.7 Hz), 2.85 (d, 1H, H-30, J¼11.8 Hz), 3.50 (t, 1H, H-100,
J¼8.7 Hz), 3.97 (d, 1H, H-300, J¼11.8 Hz), 4.02 (t, 1H, H-9b, J¼8.1 Hz),
4.43 (q,1H, H-4, J¼5.7 Hz), 6.98 (d,1H, H-6, J¼8.8 Hz), 7.29 (d,1H, H-
9, J¼1.9 Hz), 7.35 (dd, 1H, H-7, J¼8.8, 1.9 Hz); 19F NMR (376 MHz,
CDCl3): d¼2b (80%) 89.4 (d, CF3, J¼5.7 Hz), 20b (20%) 88.7 (d, CF3,
J¼6.2 Hz); 13C NMR (126 MHz, CDCl3): d¼41.0 (Me), 43.7 (C-9b),
62.2 (C-1), 62.2 (q, C-3, 4JC,F¼2.4 Hz), 75.9 (q, C-4, 2JC,F¼32.5 Hz),
90.6 (C-3a), 116.1 (C-8), 119.3 (C-6), 122.0 (q, CF3, 1JC,F¼283.0 Hz),
124.2 (C-9a), 130.9 (C-9), 131.4 (C-7), 150.7 (C-5a).
4.2.3. (3aS*,4S*,9bR*)-2-Methyl-8-methoxy-3a-nitro-4-(triﬂuorome-
thyl)-1,2,3,3a,4,9b-hexahydrochromeno[3,4-c]pyrrole (2c). Yield
77%, mp 87e88 C; IR (KBr): n¼1616, 1549, 1503, 1481, 1468, 1425,
1386, 1371 cm1; 1H NMR (400 MHz, CDCl3): d¼2.38 (s, 3H, Me),
2.43 (t, 1H, H-10, J¼8.9 Hz), 2.79 (d, 1H, H-30, J¼11.8 Hz), 3.54 (t, 1H,
H-100, J¼8.6 Hz), 3.78 (s, 3H, MeO), 4.02 (d, 1H, H-300, J¼11.8 Hz), 4.05
(t, 1H, H-9b, J¼8.8 Hz), 4.39 (q, 1H, H-4, J¼5.7 Hz), 6.64 (dd, 1H, H-9,J¼2.9, 0.7 Hz), 6.80 (ddd,1H, H-7, J¼9.0, 2.9, 0.5 Hz), 7.02 (d,1H, H-6,
J¼9.0 Hz); 19F NMR (376 MHz, CDCl3): d¼2c (91%) 89.3 (d, CF3, J
5.7 Hz), 20c (9%) 88.7 (d, CF3, J¼6.4 Hz); 13C NMR (126 MHz, CDCl3):
d¼41.0, 44.3, 55.7, 62.4, 62.5 (q, C-3, 4JC,F¼2.2 Hz), 76.3 (q, C-4,
2JC,F¼32.3 Hz), 91.2, 112.7, 114.2, 118.3, 122.2 (q, CF3, 1JC,F¼283.0 Hz),
122.8, 145.7, 155.7.
4.2.4. (3aS*,4S*,9bR*)-2-Methyl-3a,8-dinitro-4-(triﬂuoromethyl)-
1,2,3,3a,4,9b-hexahydrochromeno[3,4-c]pyrrole (2d). Yield 92%, mp
143e144 C; IR (KBr): n¼1586, 1559, 1522, 1486, 1464, 1374,
1343 cm1; 1H NMR (400MHz, CDCl3): d¼2.41 (s, 3H, Me), 2.62 (dd,
1H, H-10, J¼9.1, 7.7 Hz), 3.00 (d,1H, H-30, J¼11.8 Hz), 3.56 (t,1H, H-100,
J¼8.8 Hz), 3.91 (d, 1H, H-300, J¼11.8 Hz), 4.05 (t, 1H, H-9b, J¼7.9 Hz),
4.59 (q,1H, H-4, J¼5.6 Hz), 7.23 (d,1H, H-6, J¼9.0 Hz), 8.13 (d,1H, H-
9, J¼2.6 Hz), 8.16 (dd, 1H, H-7, J¼9.0, 2.6 Hz); 19F NMR (376 MHz,
CDCl3): d¼2d (78%) 89.5 (d, CF3, J¼5.6 Hz), 20d (27%) 88.5 (d, CF3,
J¼6.1 Hz).
4.2.5. (3aS*,4S,9bR*)-2-Methyl-3a-nitro-4-(trichloromethyl)-
1,2,3,3a,4,9b-hexahydrochromeno[3,4-c]pyrrole (2e). Yield 89%, mp
126e127 C; IR (KBr): n¼1585,1547,1491,1453,1333 cm1; 1H NMR
(400 MHz, CDCl3): d¼2.25 (t, 1H, H-10, J¼9.6 Hz), 2.42 (s, 3H, Me),
2.77 (d, 1H, H-30, J¼12.0 Hz), 3.71 (ddd, 1H, H-100, J¼8.7, 7.7, 1.0 Hz),
4.18 (dd, 1H, H-9b, J¼10.0, 7.8 Hz), 4.38 (s, 1H, H-4), 4.51 (dd, 1H,
H300, J¼12.0, 1.0 Hz), 7.09e7.17 (m, 3H, H-6, H-8, H-9), 7.27 (m, 1H,
H-7).
4.2.6. (3aS*,4S*,9bR*)-8-Bromo-2-methyl-3a-nitro-4-(trichlorome-
thyl)-1,2,3,3a,4,9b-hexahydrochromeno[3,4-c]pyrrole (2f). Yield 80%
(2f/20f¼90:10), mp 191e192 C; IR (KBr): n¼1545, 1480, 1447, 1408,
1334 cm1; 1H NMR (400 MHz, CDCl3): d¼2.25 (t, 1H, H-10,
J¼9.5 Hz), 2.42 (s, 3H, Me), 2.78 (d, 1H, H-30, J¼12.0 Hz), 3.67 (t, 1H,
H-100, J¼8.2 Hz), 4.15 (t,1H, H-9b, J¼8.8 Hz), 4.36 (s,1H, H-4), 4.48 (d,
1H, H-30 0, J¼12.0 Hz), 7.04 (d, 1H, H-6, J¼8.7 Hz), 7.27 (s, 1H, H-9),
7.37 (dd, 1H, H-7, J¼8.7, 2.2 Hz); 13C NMR (126 MHz, CDCl3): d¼41.1,
46.7, 61.7, 65.2, 86.6, 94.3, 94.8,116.3,119.3, 124.6,130.2, 131.4, 151.8.
4.2.7. (3aS*,4S*,9bR*)-2-Methyl-8-methoxy-3a-nitro-4-(trichlorom-
ethyl)-1,2,3,3a,4,9b-hexahydrochromeno[3,4-c]pyrrole (2g). Yield
85% (2g/20g¼97:3), mp 157e158 C (decomp.); IR (KBr): n¼1615,
1544, 1499, 1469, 1422, 1336 cm1; 1H NMR (400 MHz, CDCl3):
d¼2.23 (t, 1H, H-10, J¼9.5 Hz), 2.42 (s, 3H, Me), 2.74 (d, 1H, H-30,
J¼12.0 Hz), 3.68 (ddd, 1H, H-100, J¼8.7, 7.7, 1.0 Hz), 3.79 (s, 3H, MeO),
4.17 (dd, 1H, H-9b, J¼9.7, 8.0 Hz), 4.33 (s, 1H, H-4), 4.50 (dd, 1H, H-
30 0, J¼12.0, 1.0 Hz), 6.63 (d, 1H, H-9, J¼2.8 Hz), 6.81 (dd, 1H, H-7,
J¼9.0, 2.8 Hz), 7.08 (d, 1H, H-6, J¼9.0 Hz); 13C NMR (126 MHz,
CDCl3): d¼41.2, 47.2, 55.7, 61.9, 65.3, 87.1, 94.7, 95.1, 112.1, 113.9,
118.2, 123.3, 146.7, 155.9.
4.2.8. (3aS*,4S*,9bR*)-2-Methyl-3a,8-dinitro-4-(trichloromethyl)-
1,2,3,3a,4,9b-hexahydrochromeno[3,4-c]pyrrole (2h). Yield 78% (2h/
20h¼70:30), mp 217e218 C (decomp.); IR (KBr): n¼1587, 1546,
1517, 1485, 1341 cm1; 1H NMR (400 MHz, CDCl3): d¼2.34 (t, 1H, H-
10, J¼9.5 Hz), 2.45 (s, 3H, Me), 2.90 (d, 1H, H-30, J¼12.1 Hz), 3.76 (t,
1H, H-10 0, J¼8.4 Hz), 4.21 (t, 1H, H-9b, J¼8.9 Hz), 4.21 (d, 1H, H-300,
J¼12.1 Hz), 4.48 (s, 1H, H-4), 7.29 (d, 1H, H-6, J¼9.0 Hz), 8.11 (d, 1H,
H-9, J¼2.6 Hz), 8.19 (dd, 1H, H-7, J¼9.0, 2.6 Hz).
4.3. General procedure for the preparation of benzopyrano
[3,4-c]pyrrolidines oxalates (3aeh)
Anhydrous oxalic acid (0.10 g,1.1mmol) dissolved in hot acetone
(1.0 mL) was added with stirring to the solution of the corre-
sponding benzopyrano[3,4-c]pyrrolidine 2 (1.0 mmol) in acetone
(0.5 mL) and the solid formed was ﬁltered off and washed with dry
acetone to give compounds 3 as a white powder.
V.Yu. Korotaev et al. / Tetrahedron 69 (2013) 8602e860886064.3.1. (3aS*,4S*,9bR*)-2-Methyl-3a-nitro-4-(triﬂuoromethyl)-
1,2,3,3a,4,9b-hexahydrochromeno[3,4-c]pyrrole oxalate (3a). Yield
92%, mp 197e198 C (decomp.); IR (KBr): n¼1713, 1641, 1591, 1564,
1558,1496,1459,1345 cm1; 1H NMR (400MHz, DMSO-d6): d¼2.38
(s, 3H, Me), 2.45 (t, 1H, H-10, J¼9.7 Hz), 2.88 (d, 1H, H-30, J¼12.2 Hz),
3.73 (t,1H, H-100, J¼8.2 Hz), 4.02 (dd,1H, H-9b, J¼9.7, 8.2 Hz), 4.15 (d,
1H, H-300, J¼12.2 Hz), 5.42 (q, 1H, H-4, J¼6.0 Hz), 7.12 (d, 1H, H-6,
J¼8.2 Hz), 7.14 (t, 1H, H-8, J¼7.3 Hz), 7.28 (t, 1H, H-7, J¼7.6 Hz), 7.34
(d, 1H, H-9, J¼7.6 Hz); 19F NMR (376 MHz, DMSO-d6): d¼3a (96%)
90.1 (d, CF3, J¼6.0 Hz), 30a (4%) 90.4 (d, CF3, J¼6.7 Hz). Found: C,




Yield 92%, mp 187e188 C (decomp.); IR (KBr): n¼1713, 1641, 1566,
1488,1345 cm1; 1H NMR (400MHz, DMSO-d6): d¼2.38 (s, 3H, Me),
2.45 (t, 1H, H-10, J¼9.7 Hz), 2.88 (d, 1H, H-30, J¼12.2 Hz), 3.73 (t, 1H,
H-100, J¼8.2 Hz), 4.05 (dd, 1H, H-9b, J¼9.0, 8.6 Hz), 4.14 (d, 1H, H-300,
J¼12.2 Hz), 5.46 (q, 1H, H-4, J¼6.0 Hz), 7.11 (d, 1H, H-6, J¼8.7 Hz),
7.46 (dd,1H, H-7, J¼8.7, 2.2 Hz), 7.60 (d,1H, H-9, J¼2.2 Hz); (4%) 2.30
(s, 3H, Me), 2.72 (d,1H, H-30, J¼12.2 Hz), 3.44 (t, 1H, H-100, J¼8.8 Hz),
3.92 (d, 1H, H-300, J¼12.2 Hz), 4.24 (t, 1H, H-9b, J¼8.2 Hz), 7.62 (d,
1H, H-9, J¼2.2 Hz); 19F NMR (376 MHz, DMSO-d6): d¼3b (96%) 90.1
(d, CF3, J¼6.0 Hz), 30b (4%) 90.4 (d, CF3, J¼6.7 Hz). Found: C, 38.42;




Yield 98%, mp 171e172 C (decomp.); IR (KBr): n¼1727, 1617, 1567,
1504, 1461, 1438, 1345 cm1; 1H NMR (400MHz, DMSO-d6): d¼2.38
(s, 3H, Me), 2.44 (t, 1H, H-10, J¼9.6 Hz), 2.88 (d, 1H, H-30, J¼12.0 Hz),
3.73 (s, 3H, MeO), 3.75 (t, 1H, H-100, J¼8.5 Hz), 3.99 (dd, 1H, H-9b,
J¼9.4, 8.4 Hz), 4.14 (d, 1H, H-30 0, J¼12.0 Hz), 5.32 (q, 1H, H-4,
J¼6.0 Hz), 6.85 (dd, 1H, H-7, J¼8.9, 2.8 Hz), 6.90 (d, 1H, H-9,
J¼2.8 Hz), 7.04 (d, 1H, H-6, J¼8.9 Hz); 19F NMR (376 MHz, DMSO-
d6): d¼3c (96%) 90.1 (d, CF3, J¼6.0 Hz), 30c (4%) 90.4 (d, CF3,
J¼6.6 Hz); 13C NMR (126 MHz, DMSO-d6): d¼40.3, 44.4, 55.5, 60.3,
60.6, 74.6 (q, C-4, 2JC,F¼31.4 Hz), 91.1, 112.8, 114.3, 117.6, 122.1, 122.4
(q, CF3, 1JC,F¼282.2 Hz), 145.3, 155.1, 161.5 (C]O). Found: C, 45.26;
H, 3.83; N, 6.55. Calcd for C14H15F3N2O4$(CO2H)2: C, 45.51; H, 4.06;
N, 6.63.
4.3.4. (3aS*,4S*,9bR*)-2-Methyl-3a,8-dinitro-4-(triﬂuoromethyl)-
1,2,3,3a,4,9b-hexahydrochromeno[3,4-c]pyrrole oxalate (3d). Yield
93%, mp 158e159 C; IR (KBr): n¼1707, 1639, 1593, 1574,1533, 1493,
1344 cm1; 1H NMR (500 MHz, DMSO-d6): d¼2.42 (s, 3H, Me), 2.58
(t, 1H, H-10, J¼9.7 Hz), 2.99 (d, 1H, H-30, J¼12.1 Hz), 3.87 (t, 1H, H-10 0,
J¼8.1 Hz), 4.20 (d, 1H, H-300, J¼12.1 Hz), 4.22 (t, 1H, H-9b, J¼9.8 Hz),
5.69 (q, 1H, H-4, J¼5.9 Hz), 7.41 (d, 1H, H-6, J¼8.9 Hz), 8.18 (dd, 1H,
H-7, J¼8.9, 2.1 Hz), 8.36 (d, 1H, H-9, J¼2.1 Hz), 12.45 (br s, 2H, OH);
19F NMR (376 MHz, DMSO-d6): d¼3d (98%) 90.2 (d, CF3, J¼5.9 Hz),
30d (2%) 90.4 (d, CF3, J¼6.6 Hz); 13C NMR (126 MHz, DMSO-d6):
d¼40.3 (Me), 44.0 (C-9b), 60.2 (q, C-3, 4JC,F¼2.3 Hz), 60.4 (C-1), 74.6
(q, C-4, 2JC,F¼31.7 Hz), 90.0 (C-3a), 118.13 (C-6), 122.2 (q, CF3,
1JC,F¼282.1 Hz), 122.5 (C-9a), 124.0 (C-7), 125.0 (C-9), 142.9 (C-8),
156.1 (C-5a), 161.4 (C]O). Found: C, 41.12; H, 3.05; N, 9.29. Calcd for
C13H12F3N3O5$(CO2H)2: C, 41.20; H, 3.23; N, 9.61.
4.3.5. (3aS*,4S*,9bR*)-2-Methyl-3a-nitro-4-(trichloromethyl)-
1,2,3,3a,4,9b-hexahydrochromeno[3,4-c]pyrrole oxalate (3e). Yield
96%, mp 143e144 C (decomp.); IR (KBr): n¼1719, 1635, 1591, 1561,
1496,1459, 1366,1331 cm1; 1H NMR (400MHz, DMSO-d6): d¼2.41
(s, 3H, Me), 2.46 (dd, 1H, H-10, J¼10.5, 9.0 Hz), 3.15 (d, 1H, H-30,
J¼12.2 Hz), 3.78 (t, 1H, H-10 0, J¼8.0 Hz), 4.05 (dd, 1H, H-9b, J¼10.5,7.4 Hz), 4.40 (d,1H, H-300, J¼12.2 Hz), 5.33 (s, 1H, H-4), 7.11 (d,1H, H-
6, J¼8.2 Hz), 7.14 (t, 1H, H-8, J¼7.6 Hz), 7.27e7.33 (m, 2H, H-7, H-9).
Found: C, 40.62; H, 3.34; N, 6.17. Calcd for C13H13Cl3N2O3$(CO2H)2:
C, 40.79; H, 3.42; N, 6.34.
4.3.6. (3aS*,4S*,9bR*)-8-Bromo-2-methyl-3a-nitro-4-(trichlorome-
thyl)-1,2,3,3a,4,9b-hexahydrochromeno[3,4-c]pyrrole oxalate (3f).
Yield 95%, mp 175e176 C (decomp.); IR (KBr): n¼1711, 1635, 1563,
1484, 1363, 1340 cm1; 1H NMR (400 MHz, DMSO-d6): d¼2.38 (s,
3H, Me), 2.41 (t, 1H, H-10, J¼9.9 Hz), 3.08 (d, 1H, H-30, J¼12.2 Hz),
3.76 (t, 1H, H-10 0, J¼7.9 Hz), 4.06 (dd, 1H, H-9b, J¼9.9, 8.3 Hz), 4.36
(d,1H, H-300, J¼12.2 Hz), 5.39 (s, 1H, H-4), 7.10 (d, 1H, H-6, J¼8.7 Hz),
7.46 (dd, 1H, H-7, J¼8.7, 1.2 Hz), 7.54 (br s, 1H, H-9); 13C NMR
(126 MHz, DMSO-d6): d¼40.4, 46.4, 59.8, 63.1, 84.1, 93.9, 95.0, 115.1,
119.0, 124.8, 130.5, 130.8, 151.4, 161.4 (C]O). Found: C, 34.95; H,




Yield 96%, mp 172e173 C (decomp.); IR (KBr): n¼1726, 1617, 1563,
1503,1459,1434,1335 cm1; 1H NMR (400MHz, DMSO-d6): d¼2.38
(s, 3H,Me), 2.40 (t,1H, H-10, J¼10.8 Hz), 3.09 (d,1H, H-30, J¼12.2 Hz),
3.74 (s, 3H, MeO), 3.77 (t, 1H, H-100, J¼8.4 Hz), 4.00 (dd, 1H, H-9b,
J¼10.0, 7.8 Hz), 4.36 (d, 1H, H-30 0, J¼12.2 Hz), 5.23 (s, 1H, H-4),
6.84e6.88 (m, 2H, H-7, H-9), 7.04 (d, 1H, H-6, J¼8.8 Hz); 13C NMR
(126 MHz, DMSO-d6): d¼40.3, 46.8, 55.6, 59.9, 62.9, 84.6, 94.0, 95.3,
112.3, 114.1, 117.5, 122.8, 146.1, 155.2, 161.7 (C]O). Found: C, 40.46;
H, 3.42; N, 5.87. Calcd for C14H15Cl3N2O4$(CO2H)2: C, 40.74; H, 3.63;
N, 5.94.
4.3.8. (3aS*,4S*,9bR*)-2-Methyl-3a,8-dinitro-4-(trichloromethyl)-
1,2,3,3a,4,9b-hexahydrochromeno[3,4-c]pyrrole oxalate (3h). Yield
92%, mp 165e166 C (decomp.); IR (KBr): n¼1715, 1632, 1590, 1563,
1541, 1488, 1345 cm1; 1H NMR (500 MHz, DMSO-d6): d¼2.42 (s,
3H, Me), 2.52 (t, 1H, H-10, J¼9.3 Hz), 3.17 (d, 1H, H-30, J¼12.2 Hz),
3.89 (t, 1H, H-100, J¼8.0 Hz), 4.19 (dd, 1H, H-9b, J¼10.2, 8.0 Hz), 4.40
(d,1H, H-30 0, J¼12.2 Hz), 5.63 (s, 1H, H-4), 7.39 (d,1H, H-6, J¼9.0 Hz),
8.19 (dd, 1H, H-7, J¼9.0, 2.1 Hz), 8.28 (d, 1H, H-9, J¼2.1 Hz); 13C NMR
(126 MHz, DMSO-d6): d¼40.4 (Me), 46.5 (C-9b), 59.8 (C-1), 63.2 (C-
3), 83.9 (C-4), 93.3 (C-3a), 94.7 (CCl3),118.0 (C-6),123.3 (C-9a),124.0
(C-7), 124.3 (C-9), 142.9 (C-8), 156.9 (C-5a), 161.5(C]O). Found: C,
37.23; H, 2.73; N, 8.49. Calcd for C13H12Cl3N3O5$(CO2H)2: C, 37.02;
H, 2.90; N, 8.63.
4.4. Compounds 4aed
4.4.1. (6S*,6aS*,6bS*,11aR*)-6a-Nitro-6-(triﬂuoromethyl)-6,6a,6b,-
7,8,9,11,11a-octahydrochromeno[3,4-a]pyrrolizine (4a). This com-
pound was prepared from 3-nitro-2-(triﬂuoromethyl)-2H-chro-
mene (1a), proline, and paraformaldehyde according to the
described procedure for compounds 2. Yield 17%, mp 136e137 C,
colorless needles; IR (KBr): n¼1587,1549,1490,1458,1376 cm1; 1H
NMR (400MHz, CDCl3): d¼1.49e3.12 (m, 6H, 3CH2), 3.30 (dd,1H, H-
110, J¼10.7, 5.0 Hz), 3.59 (dd,1H, H-1100, J¼10.7, 7.3 Hz), 4.20 (t,1H, H-
6b, J¼7.4 Hz), 4.27 (t, 1H, H-11a, J¼6.1 Hz), 4.88 (q, 1H, H-6,
J¼6.5 Hz), 7.00 (d, 1H, H-4, J¼8.4 Hz), 7.04e7.11 (m, 2H, H-2, H-3),
7.20 (d, 1H, H-1, J¼7.1 Hz); 19F NMR (376 MHz, CDCl3): d¼94.0 (d,
CF3, J¼6.5 Hz). Found: C, 54.80; H, 4.49; N, 8.51. Calcd for
C15H15F3N2O3: C, 54.88; H, 4.61; N, 8.53.
4.4.2. (6S*,6aS*,6bS*,11aR*)-2-Bromo-6a-nitro-6-(triﬂuoromethyl)-
6,6a,6b,7,8,9,11,11a-octahydrochromeno[3,4-a]pyrrolizine (4b). This
compound was prepared from 6-bromo-3-nitro-2-(triﬂuoromethyl)-
2H-chromene (1b), proline, and paraformaldehyde according to the
described procedure for compounds 2. Yield 15%, mp 132e133 C,
V.Yu. Korotaev et al. / Tetrahedron 69 (2013) 8602e8608 8607a white powder; IR (KBr): n¼1579, 1550, 1480, 1372 cm1; 1H NMR
(500 MHz, CDCl3): d¼1.53 (ddt, 1H, H-70, J¼13.2, 8.6, 8.1 Hz), 1.85 (m,
1H, H-80), 1.94 (m, 1H, H-800), 2.12 (dtd, 1H, H-700, J¼13.2, 7.4, 4.1 Hz),
2.70 (ddd, 1H, H-90, J¼10.0, 8.5, 6.6 Hz), 3.09 (ddd, 1H, H-900, J¼10.0,
6.9, 3.8 Hz), 3.28 (dd, 1H, H-110, J¼10.8, 5.1 Hz), 3.56 (dd, 1H, H-1100,
J¼10.8, 7.2 Hz), 4.17 (t, 1H, H-6b, J¼7.5 Hz), 4.26 (dd,1H, H-11a, J¼6.5,
5.5 Hz), 4.89 (q, 1H, H-6, 3JH,F¼6.4 Hz), 6.89 (d, 1H, H-4, J¼8.4 Hz),
7.30e7.33 (m, 2H, H-1, H-3); 19F NMR (376 MHz, CDCl3): d¼93.9 (d,
CF3, J¼6.4 Hz); 13C NMR (126 MHz, CDCl3): d¼26.1 (C-8), 28.8 (C-7),
42.8 (C-11a), 55.0 (C-9), 61.1 (C-11), 70.7 (q, C-6b, 4JC,F¼2.2Hz), 74.1 (q,
C-6, 2JC,F¼32.0 Hz), 92.8 (C-6a), 115.9 (C-2), 118.9 (C-4), 122.9 (q, CF3,
1JC,F¼285.6 Hz), 124.4 (C-11b), 131.1 (C-1), 131.6 (C-3), 149.8 (C-4a).
Found: C, 44.53; H, 3.45; N, 6.83. Calcd for C15H14BrF3N2O3: C, 44.25;




2H-chromene (1f), proline, and paraformaldehyde according to the
described procedure for compounds 2. Combine yield 11%, mp
139e140 C, awhitepowder; IR (KBr): n¼1548,1481,1441,1338cm1;
1H NMR (400 MHz, CDCl3): major isomer 4c (68%) d¼1.5e3.1 (m, 6H,
3CH2), 3.28 (dd, 1H, H-110, J¼10.8, 5.6 Hz), 3.41 (dd, 1H, H-1100, J¼10.8,
7.7 Hz), 4.39 (t, 1H, H-6b, J¼6.7 Hz), 4.59 (t, 1H, H-11a, J¼7.6 Hz), 5.06
(s,1H, H-6), 6.93 (d,1H, H-4, J¼8.6 Hz), 7.30 (d,1H, H-1, J¼2.0Hz), 7.32
(dd, 1H, H-3, J¼8.6, 2.0 Hz); minor isomer 4c (32%): d¼1.90e2.05 (m,
4H, 2CH2), 2.78 (t, 1H, 110, J¼8.9 Hz), 2.86e3.08 (2H, CH2), 3.70 (t, 1H,
H-1100, J¼8.9 Hz), 4.56 (s,1H, H-6), 4.57 (t,1H, H-11a, J¼7.6 Hz), 4.61 (t,
1H,H-6b, J¼6.5Hz), 7.02 (d,1H,H-4, J¼8.6Hz), 7.19e7.22 (m,1H,H-1),
7.34e7.39 (m, 1H, H-3). Found: C, 39.38; H, 3.13; N, 6.09. Calcd for
C15H14BrCl3N2O3: C, 39.46; H, 3.09; N, 6.14.
4.4.4. (6R*,6aS*,6bS*,11aR*)-6a-Nitro-6-phenyl-6,6a,6b,7,8,9,11,11a-
octahydrochromeno[3,4-a]pyrrolizine (4d). This compound was
prepared from 3-nitro-2-phenyl-2H-chromene (1i), proline, and
paraformaldehyde according to the described procedure6e as a base
and puriﬁed by recrystallization from hexane/ether. Yield 34%, mp
161e163 C, yellow crystals; IR (KBr): n¼1611, 1587, 1535, 1489,
1457, 1374 cm1; 1H NMR (500 MHz, CDCl3): d¼1.40 (dtd, 1H, H-70,
J¼12.8, 9.1, 8.5 Hz), 1.74 (ddt, 1H, H-80, J¼12.5, 9.6, 7.5 Hz), 1.85e1.97
(m, 2H, H-700, H-800), 2.83 (ddd, 1H, H-90, J¼10.6, 8.1, 6.5 Hz), 3.21
(ddd, 1H, H-900, J¼10.6, 7.0, 4.2 Hz), 3.37 (dd, 1H, H-110, J¼11.7,
9.3 Hz), 3.43 (dd, 1H, H-1100, J¼11.7, 9.3 Hz), 3.84 (dd, 1H, H-6b,
J¼9.4, 6.8 Hz), 4.14 (t, 1H, H-11a, J¼9.3 Hz), 5.28 (s, 1H, H-6), 6.96
(dd, 1H, H-4, J¼8.1, 1.1 Hz), 7.02 (td, 1H, H-2, J¼7.5, 1.1 Hz), 7.15e7.20
(m, 2H, H-1, H-3), 7.40e7.43 (m, 5H, Ph); 13C NMR (126 MHz,
CDCl3): d¼25.0 (C-8), 30.0 (C-7), 40.4 (C-11a), 57.0 (C-9), 61.7 (C-11),
68.3 (C-6b), 78.6 (C-6), 96.1 (C-6a), 117.3 (C-4), 122.17 (C-11b),
122.21 (C-2), 127.94 (C-3), 127.96 (Co), 128.1 (Cm), 128.8 (C-1), 129.2
(Cp), 134.5 (Ci), 153.7 (C-4a). Found: C, 71.26; H, 6.08; N, 8.29. Calcd
for C20H20N2O3: C, 71.41; H, 5.99; N, 8.33.
4.5. Compounds 5a,b
4.5.1. (3aR*,9bR*)-2-Methyl-1,2,3,3a,4,9b-hexahydrochromeno[3,4-c]
pyrrole-3a-carbonitrile (5a). This compound was prepared as
a yellow oil from 3-cyano-2H-chromene (1j), sarcosine, and para-
formaldehyde according to the described procedure.6e Yield 76%,
mp >210 C (subl.), a white powder (for hydrochloride); IR (KBr):
n¼2638, 2568, 2440, 2245, 1607, 1580, 1490, 1470, 1456, 1412,
1344 cm1; 1H NMR (400MHz, CDCl3): d¼2.36 (s, 3H, Me), 2.50 (dd,
1H, H-10, J¼9.2, 7.5 Hz), 2.66 (d, 1H, H-30, J¼10.0 Hz), 3.30 (d, 1H, H-
300, J¼10.0 Hz), 3.33 (t, 1H, H-100, J¼8.7 Hz), 3.72 (t, 1H, H-9b,
J¼7.7 Hz), 3.91 (d, 1H, H-40, J¼11.2 Hz), 4.23 (d, 1H, H-400, J¼11.2 Hz),
6.95 (d, 1H, H-6, J¼8.4 Hz), 6.99 (t, 1H, H-8, J¼7.4 Hz), 7.10 (d, 1H, H-
9, J¼7.3 Hz), 7.17 (t, 1H, H-7, J¼7.7 Hz); 13C NMR (126 MHz, DMSO-d6): d¼37.5, 38.8, 41.3, 57.7, 58.1, 65.5, 117.3, 117.5, 119.8, 122.2, 129.1,
130.1, 153.0. Found: C, 62.36; H, 6.23; N, 10.88. Calcd for
C13H14N2O$HCl: C, 62.28; H 6.03; N, 11.17.
4.5.2. (3aR*,9bR*)-Methyl 2-methyl-1,2,3,3a,4,9b-hexahydrochrome
no[3,4-c]pyrrole-3a-carboxylate (5b). This compound was prepared
as a yellow oil from 3-methoxycarbonyl-2H-chromene (1k), sar-
cosine, and paraformaldehyde according to the described proce-
dure.6e Yield 83%, mp 202e204 C, a white powder (for
hydrochloride); IR (KBr): n¼2680, 2588, 2495, 2364, 1723, 1612,
1586, 1492, 1458, 1439, 1358, 1345 cm1; 1H NMR (400 MHz,
CDCl3): d¼2.34 (s, 3H, Me), 2.45e2.51 (m, 2H, H-30, H-10), 3.21 (d,
1H, H-300, J¼10.0 Hz), 3.34 (t, 1H, H-100, J¼8.5 Hz), 3.74 (s, 3H, MeO),
3.85 (d, 1H, H-40, J¼11.0 Hz), 3.92 (t, 1H, H-9b, J¼8.0 Hz), 4.38 (d, 1H,
H-400, J¼11.0 Hz), 6.89 (d, 1H, H-6, J¼8.1 Hz), 6.94 (t, 1H, H-8,
J¼7.5 Hz), 7.08e7.16 (m, 2H, H-7, H-9); 13C NMR (126 MHz, DMSO-
d6): d¼38.1, 49.2, 52.9, 57.7, 58.9, 67.3, 117.0, 120.3, 121.8, 128.2,
129.7, 153.6, 171.5 (C]O) (one C is masked). Found: C, 59.13; H,
6.49; N, 4.93. Calcd for C14H17NO3$HCl: C, 59.26; H, 6.39; N, 4.84.
4.6. X-ray diffraction study of compound 2b
Intensities of reﬂections were measured on an automatic four-
circle Xcalibur 3 diffractometer (Oxford Diffraction, Abingdon,
UK; graphite monochromated Mo Ka radiation, CCD detector, u
scanning). The structure was solved by a direct method using the
SHELX97 package.13 The hydrogen atoms were located geo-
metrically using a riding model. Nonhydrogen atoms were reﬁned
by a full-matrix least-squares method against F2 within the aniso-
tropic approximation. Final atomic coordinates, geometrical pa-
rameters, and crystallographic data have been deposited with the
Cambridge Crystallographic Data Centre (12 Union Road,
Cambridge CB2 1EZ, UK; fax: þ44 1223 336033; e-mail: depos-
it@ccdc.cam.ac.uk). The CCDC deposition number for compound 2b
is 925671. These data can be obtained free of charge from the
Cambridge Crystallographic Data Centre via http://www.ccdc.ca-
m.ac.uk/products/csd/request/.
Crystal data for 2b at 295(2) K: C13H12BrF3N2O3, M¼381.15,
a¼7.3625(14) A, b¼7.6363(12) A, c¼13.950(3) A, a¼74.399(15),
b¼78.411(15), g¼75.659(15), V¼724.2(2) A3, triclinic crystals
space group P1, Z¼2, Dc¼1.748 g cm3, m¼2.885 mm1, F(000)¼
380, 7403 reﬂections measured up to 2qmax¼56.6, 3492 unique
(Rint¼0.0309), which were used in all calculations. Reﬁnement was
converged at wR2¼0.0557 (all data), R1¼0.0324 (1551 reﬂections
with I>2s(I)), GoF¼1.001.
Acknowledgements
This work was supported ﬁnancially by the Russian Foundation
for Basic Research (Grants 11-03-00126 and 12-03-31036).
References and notes
1. Padwa, A.; Pearson, W. H. Synthetic Applications of 1,3-Dipolar Cycloaddition
Chemistry Toward Heterocycles and Natural Products; Wiley: New York, NY,
2002; Vol. 59, p169.
2. (a) Tsuge, O.; Kanemasa, S. Adv. Heterocycl. Chem. 1989, 45, 231; (b) Pandey, G.;
Banerjee, P.; Gadre, S. R. Chem. Rev. 2006, 106, 4484; (c) Najera, C.; Sansano, J. M.
Curr. Org. Chem. 2003, 7, 1105; (d) Coldham, I.; Hufton, R. Chem. Rev. 2005, 105,
2765.
3. (a) Horton, D. A.; Bourne, G. T.; Smythe, M. L. Chem. Rev. 2003, 103, 893; (b)
Razdan, R. K.; Howes, J. F. Med. Res. Rev. 1983, 3, 119.
4. (a) Dubuffet, T.; Muller, O.; Simonet, S. S.; Descombes, J.-J.; Laubie, M.;
Verbeuren, T. J.; Lavielle, G. Bioorg. Med. Chem. Lett. 1996, 6, 349; (b) Du-
buffet, T.; Newman-Tancredi, A.; Cussac, D.; Audinot, V.; Loutz, A.; Millan,
M. J.; Lavielle, G. Bioorg. Med. Chem. Lett. 1999, 9, 2059; (c) Lavielle, G.;
Dubuffet, T.; Millan, M.; Newman-Tancredi, A. U.S. Patent 5,663,191, 1997;
(d) Meyer, M. D.; Altenbach, R. J.; Basha, F. Z.; Carroll, W. A.; Drizin, I.;
Kerwin, J. F.; Wendt, M. D.; Haight, A. R.; Zhang, W. U.S. Patent 6,046,207,
2000; (e) Kiyoi, T.; Reid, M.; Francis, S.; Davies, K.; Laats, S.; McArthur, D.;
V.Yu. Korotaev et al. / Tetrahedron 69 (2013) 8602e86088608Easson, A.-M.; Kiyoi, Y.; Tarver, G.; Caulﬁeld, W.; Gibson, K.; Wishart, G.;
Morrison, A. J.; Adam, J. M.; Ray, P. Tetrahedron Lett. 2011, 52, 3413; (f)
Ghandi, M.; Taheri, A.; Abbasi, A. Tetrahedron 2010, 66, 6744; (g) Pars, H. G.;
Granchelli, F. E.; Razdan, R. K.; Keller, J. K.; Teiger, D. G.; Rosenberg, F. J.;
Harris, L. S. J. Med. Chem. 1976, 19, 445.
5. Haight, A. R.; Bailey, A. E.; Baker,W. S.; Cain,M.H.; Copp, R. R.;DeMattei, J. A.; Ford,
K. L.; Henry, R. F.; Hsu,M. C.; Keyes, R. F.; King, S. A.;McLaughlin,M. A.;Melcher, L.
M.; Nadler, W. R.; Oliver, P. A.; Parekh, S. I.; Patel, H. H.; Seif, L. S.; Staeger, M. A.;
Wayne, G. S.; Wittenberger, S. J.; Zhang, W. Org. Process Res. Dev. 2004, 8, 897.
6. (a) Grigg, R.; Vipond, D. Tetrahedron 1989, 45, 7587; (b) Grigg, R.; Idle, J.;
McMeekin, P.; Surendrakumar, S.; Vipond, D. J. Chem. Soc., Perkin Trans. 1 1988,
2703; (c) Moshkin, V. S.; Sosnovskikh, V. Y.; Slepukhin, P. A.; R€oschenthaler, G.-
V. Mendeleev Commun. 2012, 22, 29; (d) Moshkin, V. S.; Sosnovskikh, V. Y.;
R€oschenthaler, G.-V. Tetrahedron Lett. 2012, 53, 3568; (e) Moshkin, V. S.; Sos-
novskikh, V. Y.; R€oschenthaler, G.-V. Tetrahedron 2013, 69, 5884.
7. (a) Nyerges, M.; Viranyi, A.; Marth, G.; Dancso, A.; Blasko, G.; T}oke, L. Synlett
2004, 2761; (b) Viranyi, A.; Marth, G.; Dancso, A.; Blasko, G.; T}oke, L.; Nyerges,
M. Tetrahedron 2006, 62, 8720.
8. Nyerges, M.; Balazs, L.; Kadas, I.; Bitter, I.; K€ovesdi, I.; T}oke, L. Tetrahedron 1995,
51, 6783.9. (a) Organoﬂuorine Compounds in Medicinal Chemistry and Biomedical Applica-
tions; Filler, R., Kobayashi, Y., Yagupolskii, L. M., Eds.; Elsevier: Amsterdam, The
Netherlands, 1993; (b) Hiyama, T. Organoﬂuorine Compounds: Chemistry and
Application; Springer: Berlin, Germany, 2000.
10. Korotaev, V. Y.; Kutyashev, I. B.; Sosnovskikh, V. Y. Heteroat. Chem. 2005,
16, 492.
11. (a) Korotaev, V. Y.; Sosnovskikh, V. Y.; Kutyashev, I. B.; Kodess, M. I. Lett. Org.
Chem. 2005, 2, 616; (b) Korotaev, V. Y.; Sosnovskikh, V. Y.; Kutyashev, I. B.;
Kodess, M. I. Izv. Akad. Nauk, Ser. Khim. 2006, 309; [ Russ. Chem. Bull., Int. Ed.
2006, 55, 317 ]; (c) Korotaev, V. Y.; Sosnovskikh, V. Y.; Kutyashev, I. B.; Ko-
dess, M. I. Izv. Akad. Nauk, Ser. Khim. 2006, 1945; [ Russ. Chem. Bull., Int. Ed.
2006, 55, 2020 ]; (d) Korotaev, V. Y.; Sosnovskikh, V. Y.; Kutyashev, I. B. Izv.
Akad. Nauk, Ser. Khim. 2007, 1985; [ Russ. Chem. Bull., Int. Ed. 2007, 56, 2054
]; (e) Korotaev, V. Y.; Kutyashev, I. B.; Sosnovskikh, V. Y.; Kodess, M. I.
Mendeleev Commun. 2007, 17, 52; (f) Korotaev, V. Y.; Sosnovskikh, V. Y.;
Barkov, A. Y.; Slepukhin, P. A.; Ezhikova, M. A.; Kodess, M. I.; Shklyaev, Y. V.
Tetrahedron 2011, 67, 8685.
12. Korotaev, V. Y.; Sosnovskikh, V. Y.; Barabanov, M. A.; Yasnova, E. S.; Ezhikova,
M. A.; Kodess, M. I.; Slepukhin, P. A. Tetrahedron 2010, 66, 1404.
13. Sheldrick, G. M. Acta Crystallogr., Sect. A 2008, 64, 112.
